Teens Are Self-Injecting Gray-Market Retatrutide and Melanotan, TikTok Reporting Shows

What Did This Week's Reporting Describe?

Air Mail published “Teens Are Injecting Retatrutide, an Unapproved Weight-Loss Peptide Viral on TikTok” on or around 27 July 2026, describing a trend the outlet dubbed “Generation Peptide”: teenagers buying gray-market vials online and self-injecting retatrutide, melanotan and GHK-Cu after watching TikTok tutorials.[1] What the piece describes as a practice that began among bodybuilders and biohackers has, by its account, spread into US high schools. A search of the #Peptide hashtag turned up more than 342,000 videos, many walking viewers through compound “stacks,” dosing schedules and at-home injection technique.[1]

This is not an isolated report. The Wall Street Journal documented the same broader pattern among teen boys and young men in a 16 May 2026 feature, noting the injectable products in question have not undergone FDA approval and that users routinely push past explicit safety warnings.[2] RNZ reported a New Zealand-specific version of the story on 24 April 2026, and ScienceAlert flagged a melanotan-specific dermatology concern around early July.[3][4] Four separate outlets, across three months, describe the same escalating pattern rather than a single viral moment.

Which Compounds Are Being Named, and Why?

Air Mail's reporting names three compounds most consistently.[1] Retatrutide, an investigational GIP/GLP-1/glucagon triple agonist still in Eli Lilly's Phase 3 TRIUMPH programme, is used by the trend's participants as a purportedly stronger alternative to approved GLP-1 medicines. Melanotan, a synthetic tanning peptide, is used to darken skin without sun exposure. GHK-Cu, a copper peptide most often researched for its role in collagen signalling, is marketed on TikTok for skin appearance.[1] None of the three is licensed for human use anywhere in the world.

The melanotan strand of the trend has its own dedicated coverage: ScienceAlert reported dermatologists' concern that the peptide can cause existing moles to darken or enlarge, potentially masking the early visual signs clinicians rely on to catch melanoma, and noted melanotan is banned as a cosmetic product in the UK, US, Australia and Denmark, among other countries.[4] Velox Peptides' own melanotan-II research guide and GHK-Cu research guide cover the preclinical literature on both peptides for laboratory audiences; neither guide, nor this one, provides human dosing information.

What Do Doctors Say About the Health Risks?

Dr David Gerrard, Emeritus Professor of Sports Medicine at the University of Otago, told RNZ that long-term, unsupervised use of synthetic peptides carries “far too many risks without medical supervision” and warned it could cause “irreversible damage” to organs.[3] Gerrard noted no human studies have established the long-term safety of these compounds at the doses and frequencies reportedly used, and that claimed benefits such as muscle growth or fat loss are not supported by controlled evidence in this population.[3]

The Wall Street Journal's reporting reached a similar conclusion from a different angle: the injectable products driving the trend have not undergone FDA approval, and users interviewed described continuing despite explicit warnings from the sellers' own listings.[2]

How Are Unregulated Sellers Exploiting “Research Use Only” Labelling?

“Research use only” and “not for human consumption” are legitimate labelling conventions for genuine laboratory reagents, including the compounds Velox Peptides supplies. Air Mail's reporting describes sellers using identical wording on products marketed with injection tutorials, dosing charts and lifestyle content aimed squarely at human self-administration — the label used as a legal loophole rather than an accurate description of the product's intended use.[1] Our earlier coverage of the compounding grey market documents the same pattern in a separate, adult-focused telehealth context.[5]

What Should UK Researchers Take From This?

None of the compounds named in this reporting have any UK marketing authorisation for human use, and nothing here changes their underlying research pharmacology. The Human Medicines Regulations 2012 already prohibit selling an unlicensed medicine for human administration in the UK, a rule that applies regardless of how a product is labelled online. See our guide on whether research peptides are legal in the UK for the fuller legal picture.

The distinction this site draws consistently applies here too: a research reagent sold with batch-level HPLC verification, explicit laboratory-use framing and no dosing guidance sits in an entirely different category from an unlabelled vial marketed alongside injection tutorials on social media. The reporting summarised in this article concerns the latter, not any product Velox Peptides supplies.

Compounds discussed are supplied by Velox Peptides as research reagents only. Not medicines. Not for human or veterinary use. Not evaluated by the MHRA or FDA for any therapeutic purpose. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions